643 related articles for article (PubMed ID: 17553067)
1. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: 'bile ductular carcinoma'.
Kozaka K; Sasaki M; Fujii T; Harada K; Zen Y; Sato Y; Sawada S; Minato H; Matsui O; Nakanuma Y
Histopathology; 2007 Sep; 51(3):390-400. PubMed ID: 17553067
[TBL] [Abstract][Full Text] [Related]
2. The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma.
Aishima S; Asayama Y; Taguchi K; Sugimachi K; Shirabe K; Shimada M; Sugimachi K; Tsuneyoshi M
Mod Pathol; 2002 Nov; 15(11):1181-90. PubMed ID: 12429797
[TBL] [Abstract][Full Text] [Related]
3. The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver.
Maeda T; Kajiyama K; Adachi E; Takenaka K; Sugimachi K; Tsuneyoshi M
Mod Pathol; 1996 Sep; 9(9):901-9. PubMed ID: 8878022
[TBL] [Abstract][Full Text] [Related]
4. Combined hepatocellular carcinoma and cholangiocarcinoma with components of mucinous carcinoma arising in a cirrhotic liver.
Morita D; Kagata Y; Ogata S; Tsuda H; Hatsuse K; Mochizuki H; Matsubara O
Pathol Int; 2006 Apr; 56(4):222-6. PubMed ID: 16634969
[TBL] [Abstract][Full Text] [Related]
5. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
Abe N; Watanabe T; Izumisato Y; Suzuki Y; Masaki T; Mori T; Sugiyama M; Fusco A; Atomi Y
J Gastroenterol; 2003; 38(12):1144-9. PubMed ID: 14714251
[TBL] [Abstract][Full Text] [Related]
6. Intrahepatic clear cell cholangiocarcinoma: immunohistochemical aspects in a very rare type of cholangiocarcinoma.
Haas S; Gütgemann I; Wolff M; Fischer HP
Am J Surg Pathol; 2007 Jun; 31(6):902-6. PubMed ID: 17527078
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma.
Zimmerman RL; Fogt F; Burke M; Murakata LA
Oncol Rep; 2002; 9(4):689-92. PubMed ID: 12066193
[TBL] [Abstract][Full Text] [Related]
8. Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas.
Somorácz A; Tátrai P; Horváth G; Kiss A; Kupcsulik P; Kovalszky I; Schaff Z
Hum Pathol; 2010 Sep; 41(9):1310-9. PubMed ID: 20471664
[TBL] [Abstract][Full Text] [Related]
9. Hepatocarcinoma-intestine-pancreas/pancreatic associated protein (HIP/PAP) is expressed and secreted by proliferating ductules as well as by hepatocarcinoma and cholangiocarcinoma cells.
Christa L; Simon MT; Brezault-Bonnet C; Bonte E; Carnot F; Zylberberg H; Franco D; Capron F; Roskams T; Bréchot C
Am J Pathol; 1999 Nov; 155(5):1525-33. PubMed ID: 10550309
[TBL] [Abstract][Full Text] [Related]
10. Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma.
Ramalho FS; Ramalho LN; Della Porta L; Zucoloto S
J Gastroenterol Hepatol; 2006 Aug; 21(8):1276-80. PubMed ID: 16872309
[TBL] [Abstract][Full Text] [Related]
11. α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression.
Ikeda H; Sato Y; Yoneda N; Harada K; Sasaki M; Kitamura S; Sudo Y; Ooi A; Nakanuma Y
Hum Pathol; 2012 Nov; 43(11):1955-63. PubMed ID: 22516245
[TBL] [Abstract][Full Text] [Related]
12. A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma.
Wakasa T; Wakasa K; Shutou T; Hai S; Kubo S; Hirohashi K; Umeshita K; Monden M
Hepatogastroenterology; 2007 Mar; 54(74):508-13. PubMed ID: 17523309
[TBL] [Abstract][Full Text] [Related]
13. Sarcomatous cholangiocarcinoma.
Gupta K; Powari M; Dey P
Diagn Cytopathol; 2003 Mar; 28(3):168-9. PubMed ID: 12619101
[No Abstract] [Full Text] [Related]
14. Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma.
Batmunkh E; Tátrai P; Szabó E; Lódi C; Holczbauer A; Páska C; Kupcsulik P; Kiss A; Schaff Z; Kovalszky I
Hum Pathol; 2007 Oct; 38(10):1508-15. PubMed ID: 17640714
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma.
Okuda H; Shiratori K; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2006 May; 21(5):869-73. PubMed ID: 16704538
[TBL] [Abstract][Full Text] [Related]
16. Mixed hepatocellular-cholangiocarcinoma may derive from "hepatogones".
Hunt JP; Varnholt H
Hepatobiliary Pancreat Dis Int; 2008 Feb; 7(1):105; author reply 105-6. PubMed ID: 18234649
[No Abstract] [Full Text] [Related]
17. Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas.
Okamura N; Yoshida M; Shibuya A; Sugiura H; Okayasu I; Ohbu M
Pathol Int; 2005 Nov; 55(11):724-31. PubMed ID: 16271085
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological analysis of colorectal cancer liver metastasis and intrahepatic cholangiocarcinoma: are they just apples and oranges?
Chiu CT; Chiang JM; Yeh TS; Tseng JH; Chen TC; Jan YY; Chen MF
Dig Liver Dis; 2008 Sep; 40(9):749-54. PubMed ID: 18329969
[TBL] [Abstract][Full Text] [Related]
19. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
[TBL] [Abstract][Full Text] [Related]
20. Primary liver carcinoma arising in people younger than 30 years.
Klein WM; Molmenti EP; Colombani PM; Grover DS; Schwarz KB; Boitnott J; Torbenson MS
Am J Clin Pathol; 2005 Oct; 124(4):512-8. PubMed ID: 16146811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
